52
Antares Therapeutics, Inc. raises $40M under Reg D
Company raise · Closed · Offering $40M · Sold $40M · BOSTON, MA · filed 2025-03-12
55
Antares Therapeutics, Inc. raises $30M under Reg D
Company raise · Raising · BOSTON, MA · Form D filed 2025-05-15
$50M+ raise
How this compares
- Among 439 fund launches filed from MA in the same window it is larger than 84%; the MA median is $2M.
- No earlier fund launch by this sponsor appears on EDGAR.
Computed from every Form D fund launch on EDGAR since late 2024, not sampled. Amounts are the stated offering size; indefinite offerings are excluded.
Raise progress
| Filed | Form | Sold | Investors | Change |
|---|---|---|---|---|
| 2025-03-12 | D | $40M | 3 | |
| 2025-05-15 | D | $30M | 35 | −$10M |
Amount sold and investor count as restated on each of the issuer's Form D filings. A rise since the previous filing is capital closed in between.
Antares Therapeutics on EDGAR
Earlier and related filings by the same issuer and sponsor.
People on the filing
| Andrew Fedder | Executive Officer |
| Menelas N. Pangalos | Director |
| Jeffrey Albers | Director |
| Keith Flaherty | Director |
| Jean-Francois Formela | Director |
| Adam Friedman | Executive Officer, Director |
| Brian Piper | Executive Officer |
| Shelley Chu | Director |
[email protected] · observed Work emails for the people on the filing, labelled by confidence — subscribers
Signed by Andrew Fedder, General Counsel.
Why now — by persona
Relevant to: Executive & technical recruiting, B2B software & services sales, Commercial banking / treasury, D&O and management-liability insurance, Outsourced accounting / CFO.
Filing contact
The issuer's phone number and address from the filing are shown to subscribers. See plans.